Month: January 2024

Ivry-sur-Seine – France, January 31, 2024 – 6:45 pm CET TERMINATION OF THE LIQUIDITY PROVIDING CONTRACT ENTRUSTED TO NATIXIS ODDO BHF FNAC DARTY (ISIN FR0011476928) announces that after the close of trading on January 31, 2024, the Liquidity contract entrusted to investment firm NATIXIS ODDO BHF since September 26, 2018 was terminated. At the close of trading on January 31, 2024, the following resources were recorded on the liquidity account:         144,654 FNAC DARTY shares, €660,824.76As a reminder, as of the last statement on this agreement, December 31, 2023, the following resources were recorded on the liquidity account:134,676 FNAC DARTY shares, €917,138.56As a reminder, as of the implementation of the Liquidity Contract, September 26, 2018, the following resources were recorded on the liquidity account:97,750 FNAC DARTY...

Restatement of 9M23 distributable net income Paris, 31 January 2024,Distributable Net Income in the first nine months of 2023 was restated to reflect the reclassification of exceptional items recorded in the nine months of 2023 into extraordinary items and to take into account additional adjustments. These extraordinary items and other additional adjustments are excluded from distributable Net Income of the first nine months of 2023 in order to reflect the BNP Paribas Group’s intrinsic performance through distributable Net Income.​ After restatement of +€415m, distributable Net Income in the first nine months of 2023 therefore amounts to €9,225 m (€8,810m before the restatement). Details of the restatement are available at:Investors & Shareholders | BNP Paribas BankAttachment2023 Recomposition Distribuable –...

WASHINGTON, Jan. 31, 2024 (GLOBE NEWSWIRE) — 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharmaceuticals” or the “Company”), specialists in developing and marketing new medicines for the treatment and prevention of infectious diseases, announced today the closing of its public offering of 5,260,901 units (the “Units”) at a price to the public of $0.385 per Unit and 999,076 pre-funded units (the “Pre-Funded Units”) at a price to the public of $0.375 per Pre-Funded Unit. Each Unit consists of one share of common stock and one warrant exercisable for one share of common stock (the “Warrant”). Each Warrant has an exercise price of $0.4235 per share, is exercisable immediately upon issuance and expires five years from the date of issuance. Each Pre-Funded Unit consists of one pre-funded warrant exercisable for...

Common Stock Will Begin Trading on Split-Adjusted Basis on February 2, 2024 Westport, CT, Jan. 31, 2024 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 10 pre-split shares. The reverse stock split will become effective at 4:05 p.m. New York Time on Thursday, February 1, 2024. BioSig’s common stock will continue to trade on the Nasdaq Capital Market under the symbol BSGM. It will begin trading on a split-adjusted basis when the market opens on Friday, February 2, 2024. The new CUSIP number for the common stock...

TORONTO, Jan. 31, 2024 (GLOBE NEWSWIRE) — Blockmate Ventures Inc (TSX.V: MATE) (OTCQB: MATEF) (FSE: 8MH1) (“Blockmate” or the “Company”), an innovative investment firm in the blockchain technology space, proudly announces that its investee, Hivello Holdings, has secured a further USD $1.5 million after receiving strong interest from investors following the announcement of a USD $1 million raise in December 2023. Due to the overwhelming interest, of the additional USD $1.5 million, USD $1 million was raised at a pre-money valuation of $9 million – an 80% premium to the round which just closed in December 2023. The additional $1.5 million brings the total raised to $2.5 million. The funding was secured as a Simple Agreement for Future Equity (SAFE) instrument fundraising round. Consequently once converted, the post-money implied...

Company announcement – No. 7 / 2024 Total number of shares and voting rights in Zealand Pharma at January 31, 2024 Copenhagen, Denmark, January 31, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end of a calendar month during which there have been changes to its share capital.  In Company announcement No. 3/2024 from January 12, 2024, Zealand announced an increase in share capital relating to private placement. Following these announcements, the table below lists the total number of shares and voting rights in Zealand up to and including January 31,...

BROOKFIELD NEWS, Jan. 31, 2024 (GLOBE NEWSWIRE) — Brookfield Corporation (TSX: BN, NYSE: BN) will host its fourth quarter 2023 conference call and webcast on Thursday, February 8, 2024 at 10:00am (ET). Results will be released that morning before 7:00am (ET) and available on our website at https://bn.brookfield.com/news-events/press-releases. Participants can join by conference call or webcast: Conference CallPlease pre-register by conference call: https://register.vevent.com/register/BId6d208f8e3d945d3895a5237b545f122 Upon registering, you will be emailed a dial-in number, and unique PIN. This process will bypass the operator and avoid the queue.WebcastPlease join and register by webcast: https://edge.media-server.com/mmc/p/k46r888g Replay of the event is available on the above webcast link for 90 days.About Brookfield...